METHOD OF TREATING RENAL CELL CARCINOMA Russian patent published in 2020 - IPC A61K31/664 A61K38/19 A61P35/00 G01N33/574 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and aims at treating renal cell carcinoma. Combination of preparations is administered to a patient: 3 times a week in amount of 12000000 ME per day and Endoxane. Endoxane is orally administered in amount of 50 mg a day and additionally subcutaneously in amount of 200,000 units a day, twice a week. Computed tomography is performed every 8 weeks. If observing X-ray signs of disease progression, the levels of spontaneous production of IL-10 (X1), induced production of IL-8 (X2), spontaneous production of IL-4 (X3), induced TNF-α (X4) and absolute concentration of natural killers with T-lymphocyte receptors CD3+CD16+56+(X5). Discriminant functions F1 and F2 are calculated from obtained values. If F1>F2 treatment is continued in previous mode. If F2>F1, the patient is transferred to sunitinib therapy. Between 8-week sunitinib cycles, 2-week pause is performed.

EFFECT: invention enables improving survival rates in patients with renal cell carcinoma.

1 cl, 13 tbl, 1 ex